Sands Capital Ventures’s Acrivon Therapeutics ACRV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $2.53M | Hold |
2,122,605
| – | – | 0.5% | 17 |
|
|
2025
Q1 | $4.31M | Hold |
2,122,605
| – | – | 1.05% | 13 |
|
|
2024
Q4 | $12.8M | Hold |
2,122,605
| – | – | 2.78% | 8 |
|
|
2024
Q3 | $14.9M | Hold |
2,122,605
| – | – | 4.18% | 5 |
|
|
2024
Q2 | $12.3M | Buy |
2,122,605
+470,000
| +28% | +$2.73M | 4.12% | 6 |
|
|
2024
Q1 | $11.8M | Hold |
1,652,605
| – | – | 2.85% | 8 |
|
|
2023
Q4 | $8.13M | Hold |
1,652,605
| – | – | 2.26% | 9 |
|
|
2023
Q3 | $15.8M | Hold |
1,652,605
| – | – | 4.67% | 9 |
|
|
2023
Q2 | $21.4M | Hold |
1,652,605
| – | – | 6.34% | 7 |
|
|
2023
Q1 | $21M | Hold |
1,652,605
| – | – | 5.18% | 8 |
|
|
2022
Q4 | $19M | Buy |
+1,652,605
| New | +$19M | 5.21% | 7 |
|